738577-08-7

Usage

Uses

Used in Pharmaceutical Synthesis:
4-Ethynylpiperidine is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to participate in a wide range of chemical reactions, contributing to the development of new and innovative medications.
Used in Agrochemical Production:
In the agrochemical industry, 4-Ethynylpiperidine serves as an essential building block for the creation of various agrochemicals, including pesticides and herbicides, due to its versatile reactivity and compatibility with different chemical processes.
Used in Organic Compound Synthesis:
4-Ethynylpiperidine is utilized as a versatile starting material in the synthesis of a broad spectrum of organic compounds, taking advantage of its unique structure and reactivity to form complex molecules for various applications.
Used in Metal-Catalyzed Reactions:
As a potential ligand in metal-catalyzed reactions, 4-Ethynylpiperidine plays a crucial role in facilitating specific chemical transformations, enhancing the efficiency and selectivity of these processes in organic synthesis.
Overall, 4-Ethynylpiperidine's diverse applications across different industries highlight its importance as a valuable intermediate and building block in the chemical and pharmaceutical sectors.

InChI:InChI=1/C7H11N/c1-2-7-3-5-8-6-4-7/h1,7-8H,3-6H2

Upstream product

• 287192-97-6 4-ethynyl-piperidine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 848411-82-5 (3-{4-[5-(2,3-dichloro-4-triisopropylsilanyloxy-phenyl)-2-methyl-2H-pyrazol-3-yl]-piperidine-1-sulfonylamino}-propyl)-methyl-carbamic acid tert-butyl ester 
• 848411-85-8 5-[4-(5-{1-[3-(tert-butoxycarbonyl-methyl-amino)-propylsulfamoyl]-piperidin-4-yl}-1-methyl-1H-pyrazol-3-yl)-2,3-dichloro-phenoxymethyl]-furan-2-carboxylic acid 
• 848411-83-6 5-[4-(5-{1-[3-(tert-butoxycarbonyl-methyl-amino)-propylsulfamoyl]-piperidin-4-yl}-1-methyl-1H-pyrazol-3-yl)-2,3-dichloro-phenoxymethyl]-furan-2-carboxylic acid ethyl ester 
• 515846-36-3 (R)-[1-(2-{4-[5-(2,3-dichloro-4-hydroxy-phenyl)-2-methyl-2H-pyrazol-3-yl]-piperidin-1-yl}-2-oxo-ethylcarbamoyl)-3-methyl-butyl]-carbamic acid tert-butyl ester 
• 515846-52-3 (R)-[1-(2-{4-[5-(2,3-dichloro-4-methoxy-phenyl)-2-methyl-2H-pyrazol-3-yl]-piperidin-1-yl}-2-oxo-ethylcarbamoyl)-3-methyl-butyl]-carbamic acid tert-butyl ester 
• 515846-33-0 (R)-[1-(2-{4-[3-(2,3-dichloro-4-triisopropylsilanyloxy-phenyl)-3-oxo-prop-1-ynyl]-piperidin-1-yl}-2-oxo-ethylcarbamoyl)-3-methyl-butyl]-carbamic acid tert-butyl ester 
• 515846-35-2 (R)-[1-(2-{4-[5-(2,3-dichloro-4-triisopropylsilanyloxy-phenyl)-2-methyl-2H-pyrazol-3-yl]-piperidin-1-yl}-2-oxo-ethylcarbamoyl)-3-methyl-butyl]-carbamic acid tert-butyl ester 
• 515846-39-6 (R)-5-[4-(5-{1-[2-(2-tert-butoxycarbonylamino-4-methyl-pentanoylamino)acetyl]-piperidin-4-yl}-1-methyl-1H-pyrazol-3-yl)-2,3-dichloro-phenoxymethyl]furan-2-carboxylic acid methyl ester 
• 515846-48-7 (R)-3-[4-(5-{1-[2-(2-tert-butoxycarbonylamino-4-methyl-pentanoylamino)acetyl]-piperidin-4-yl}-1-methyl-1H-pyrazol-3-yl)-2,3-dichloro-phenoxymethyl]benzoic acid 
• 515846-59-0 (R)-4-[4-(5-{1-[2-(2-tert-butoxycarbonylamino-4-methyl-pentanoylamino)acetyl]-piperidin-4-yl}-1-methyl-1H-pyrazol-3-yl)-2,3-dichloro-phenoxymethyl]benzoic acid 

Relevant academic research and scientific papers

TARGETED BIFUNCTIONAL DEGRADERS

The present invention provides, in one aspect, bifunctional compounds that can be used to promote or enhance degradation of certain circulating proteins. In another aspect, the present invention provides bifunctional compounds that can be used to promote or enhance degradation of certain autoantibodies. In certain embodiments, treatment or management of a disease and/or disorder requires degradation, removal, or reduction in concentration of the circulating protein or the autoantibody in the subject. Thus, in certain embodiments, administration of a compound of the invention to the subject removes or reduces the circulation concentration of the circulating protein or the autoantibody, thus treating, ameliorating, or preventing the disease and/or disorder. In certain embodiments, the circulating protein is TNF.

BIFUNCTIONAL SMALL MOLECULES TO TARGET THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS

The present invention is directed to bifunctional small molecules which contain a circulating protein binding moiety (CPBM) linked through a linker group to a cellular receptor binding moiety (CRBM) which is a membrane receptor of degrading cell such as a hepatocyte or other degrading cell. In embodiments, the (CRBM) is a moiety which binds to asialoglycoprotein receptor (an asialoglycoprotein receptor binding moiety, or ASGPRBM) of a hepatocyte. In additional embodiments, the (CRBM) is a moiety which binds to a receptor of other cells which can degrade proteins, such as a LRP1, LDLR, FcyRI, FcRN, Transferrin or Macrophage Scavenger receptor. Pharmaceutical compositions based upon these bifunctional small molecules represent an additional aspect of the present invention. These compounds and/or compositions may be used to treat disease states and conditions by removing circulating proteins through degradation in the hepatocytes or macrophages of a patient or subject in need of therapy. Methods of treating disease states and/or conditions in which circulating proteins are associated with the disease state and/or condition are also described herein.

Design and synthesis of novel triazolo-lapatinib hybrids as inhibitors of breast cancer cells

A series of triazolo-lapatinib hybrids were synthesized via copper (II)-oxide nanoparticle (Cu2O-NP)-catalyzed azide-alkyne cycloaddition. The ability of these compounds to reduce the viability of breast cancer SKBR3 and SUM159 cells and stem cell-like KG-1a leukemia cells was subsequently evaluated. Compared with lapatinib, compounds 6c–f were more potent than lapatinib against the three cell lines. Next, the toxicity of compounds 6c–f was assessed in zebrafish. Compound 6d had comparable toxicity with lapatinib at 200 μM (mortality rate = 10 vs. 10%), and compound 6e had lower toxicity than lapatinib at 200 μM (mortality rate = 0 vs. 10%). Thus, compound 6e is a promising lead compound worthy of further investigation. [Figure not available: see fulltext.].

Identification of nonpeptidic small-molecule inhibitors of interleukin-2

The identification, design, and synthesis of a series of novel sulfamide- and urea-based small-molecule antagonists of the protein-protein interaction IL-2/IL-2Rα are described. Installation of a furan carboxylic acid fragment onto a low-micromolar sulfamide resulted in a 23-fold improvement in activity, providing a sub-micromolar, nonpeptidic IL-2 inhibitor (IC 50 = 0.60 μM).

Discovery of a potent small molecule IL-2 inhibitor through fragment assembly

Using a site-directed fragment discovery method called tethering, we have identified a 60 nM small molecule antagonist of a cytokine/receptor interaction (IL-2/IL2Rα) with cell-based activity. Starting with a low micromolar hit, we employed a combination